Roche Holding AG
SIX:RO

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:RO
Watchlist
Price: 356.4 CHF 1.08% Market Closed
Market Cap: 246.1B CHF

Operating Margin

33.8%
Current
Improving
by 1.6%
vs 3-y average of 32.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.8%
=
Operating Income
CHf20.8B
/
Revenue
CHf61.6B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
33.8%
=
Operating Income
CHf20.8B
/
Revenue
CHf61.6B

Peer Comparison

Country Company Market Cap Operating
Margin
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Novartis AG
SIX:NOVN
221.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
DE
Bayer AG
XETRA:BAYN
40.8B EUR
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
UK
AstraZeneca PLC
LSE:AZN
217.9B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
No Stocks Found

Market Distribution

Higher than 90% of companies in Switzerland
Percentile
90th
Based on 1 016 companies
90th percentile
33.8%
Low
-62 472.2% — 4.5%
Typical Range
4.5% — 17.1%
High
17.1% — 91.2%
Distribution Statistics
Switzerland
Min -62 472.2%
30th Percentile 4.5%
Median 11.2%
70th Percentile 17.1%
Max 91.2%

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

RO Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
33.8%
=
Operating Income
CHf20.8B
/
Revenue
CHf61.6B
What is Roche Holding AG's current Operating Margin?

The current Operating Margin for Roche Holding AG is 33.8%, which is above its 3-year median of 32.2%.

How has Operating Margin changed over time?

Over the last 3 years, Roche Holding AG’s Operating Margin has increased from 31.4% to 33.8%. During this period, it reached a low of 31.2% on Jun 30, 2023 and a high of 33.8% on Jun 30, 2025.

Back to Top